Relmada Therapeutics (RLMD) Cash from Financing Activities (2012 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Cash from Financing Activities data on file, last reported at $156.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $156.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $250.0 million (changed N/A YoY), and the FY2025 annual result was $93.6 million, up 232034.78% from the prior year.
• Cash from Financing Activities rose to $156.6 million in Q1 2026 per RLMD's latest filing, from $93.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $156.6 million in Q1 2026 and troughed at -$172487.0 in Q4 2024.
• A 4-year average of $32.8 million and a median of $569092.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities plunged 99.75% in 2022, then surged 54386.89% in 2025.
• A 4-year view of Cash from Financing Activities shows it stood at $409883.0 in 2022, then slumped by 142.08% to -$172487.0 in 2024, then surged by 54386.89% to $93.6 million in 2025, then jumped by 67.21% to $156.6 million in 2026.
• Business Quant data shows RLMD's Cash from Financing Activities at $156.6 million in Q1 2026, $93.6 million in Q4 2025, and -$172487.0 in Q4 2024.